Timothy C Rodell MD
Critical Care Medicine, Pleural Disease
Chief Executive Officer Aethlon Medical, Inc.
Join to View Full Profile
201 Midland AveAspen, CO 81611
Phone+1 970-948-5844
Fax+1 970-948-5844
Dr. Rodell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1984 - 1987- University of ColoradoResidency, Internal Medicine, 1980 - 1984
University of North Carolina at Chapel Hill School of MedicineClass of 1980
Certifications & Licensure
CO State Medical License 1981 - 2025
Clinical Trials
- Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD Start of enrollment: 2001 Jul 01
Publications & Presentations
PubMed
- 12 citationsA Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander S. Rosemurgy, Sharona Ross
Journal of Pancreatic Cancer. 2021-03-23 - 24 citationsWhole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.Allen Lee Cohn, Michael A. Morse, Bert H. O'Neil, Samuel Whiting, Claire Coeshott
Journal of Immunotherapy. 2018-04-01 - 11 citationsGI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against TuberculosisThomas H. King, Crystal A. Shanley, Zhimin Guo, Donald Bellgrau, Timothy C. Rodell
Clinical and Vaccine Immunology. 2017-12-05
Press Mentions
- Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. As Chief Executive OfficerNovember 3rd, 2020
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. As Chief Executive OfficerNovember 3rd, 2020- FDA Approves Aethlon Medical’s IDE Supplement for Covid-19 PatientsJune 19th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
